The company operates without revenue, resulting in persistent operating losses that reached a peak of $15.4 million in 2025Q3 due to intensive R&D spending.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 35.5M | 18.35M | 11.18M | 4.73M | 978.42K | 1.44M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 20.69M | 17.92M | 7.65M | 2.46M | 332.03K | 258.01K |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 17.14M | 7.72M | 3.53M | 193.58K | 646.38K | 1.18M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | -7.29M | 0 | 2.07M | 0 | 0 |
| Operating Income | -35.5M | -18.35M | -11.18M | -4.73M | -978.42K | -1.44M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -64.13% | -136.39% | -383.43% | 32.12% | - |
| EBITDA | -35.5M | -18.35M | -11.16M | -2.66M | -1.17M | -1.94M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -161.49% | -64.5% | -319.64% | -128.08% | 39.92% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 2.07M | 0 | 0 |
| EBIT | -35.5M | -18.35M | -11.16M | -2.66M | -1.17M | -1.94M |
| Net Interest Income | 230.63K | -141.26K | -213.13K | -584.82K | -1.1M | -690.85K |
| Interest Income | 51.58K | 0 | 104.41K | 10.72K | -575.45K | -575.45K |
| Interest Expense | -179.05K | 141.26K | 317.54K | 595.54K | 526.83K | 115.41K |
| Other Income/Expense | -1.43M | -7.02M | 25.39K | -584.82K | -713.97K | -613.88K |
| Pretax Income | -36.93M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -36.93M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -155.31% | -127.39% | -109.9% | -214.04% | 17.66% | - |
| Net Income (Continuing) | -36.93M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 101.84K | 104.86K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.25 | -1.96 | -1.16 | -1.06 | -0.21 | -0.26 |
| EPS Growth % | -48.65% | -68.97% | -9.43% | -404.76% | 19.23% | - |
| EPS (Basic) | - | -1.96 | -1.16 | -1.53 | -0.88 | -0.26 |
| Diluted Shares Outstanding | 29.54M | 17.28M | 9.62M | 5.03M | 8.05M | 8.05M |
| Basic Shares Outstanding | 29.54M | 17.28M | 9.62M | 3.48M | 1.93M | 8.05M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Clinical trial funding dependency
As reported in recent financial statements, Medicus Pharma's R&D expenditures reached a peak of $10.4 million in 2025Q3, reflecting the intensive capital requirements of the SkinJect clinical development program which currently dominates the company's cost structure and dictates the overall pace of its cash consumption.
The volatility in R&D spending suggests a project-based cost profile that is highly sensitive to clinical trial milestones and patient enrollment phases. Investors should monitor whether these periodic spikes in expenditure translate into meaningful regulatory progress or if they indicate potential inefficiencies in trial management.
Based on the company's reported figures, operating losses have fluctuated significantly, reaching a high of $15.4 million in 2025Q3, which underscores the absence of revenue to offset the fixed overhead and clinical trial costs inherent in the current pre-revenue business model of the firm.
The lack of operating leverage is expected for a clinical-stage entity, yet the magnitude of the quarterly losses relative to the $8.7 million cash position warrants caution. This suggests that the company's ability to scale operations is currently tethered to external financing rather than internal cash generation.
According to historical income statements, the company's net income is consistently negative, with EPS dilution exacerbated by periodic stock-based compensation and non-operating items that complicate the assessment of core operational performance for investors evaluating the long-term viability of the SkinJect platform's development path.
The presence of stock-based compensation, while modest, adds a layer of dilution that investors must account for when modeling future equity requirements. The lack of revenue recognition means that net income figures are currently secondary to the burn rate and the probability-adjusted value of the lead asset.
With a debt-to-equity ratio of 107.09% as noted in recent disclosures, the company faces a precarious financial position where the reliance on debt to fund clinical trials may create significant pressure on future equity holders if the lead asset fails to meet its primary clinical endpoints.
Short-sellers would likely focus on the high leverage and the limited cash runway, which may necessitate dilutive capital raises at unfavorable valuations. The combination of high debt and zero revenue suggests that the company's financial flexibility is extremely limited, potentially forcing management into suboptimal financing decisions.
Quick answers to the most common questions about buying MDCXW stock.
For fiscal year 2025, Medicus Pharma Ltd. (MDCXW) reported total revenue of $0.0M.
Medicus Pharma Ltd. (MDCXW) reported a net loss of $25.4M for the fiscal year ending 2025.